New generation of drugs show early efficacy against drug-resistant TB.

[2greys]

New treatment regimens for multidrug-resistant tuberculosis (MDR-TB) have shown early effectiveness in 85 percent of patients in a cohort that included many people with serious comorbidities that would have excluded them from clinical trials, according to the results of a new international study.

The results, based on observational data from a diverse cohort of patients in 17 countries, underscore the need for expanded access to the recently developed TB medicines bedaquiline and delamanid. By contrast, the historical standard of care, still in use in much of the world, has approximately 60 percent treatment efficacy globally.

The study was published July 24, 2020, in the American Journal of Respiratory and Critical Care Medicine.

hms.harvard.edu/news/promis...

American Journal of Respiratory and Critical Care Medicine

atsjournals.org/doi/10.1164...

[Angelagone]

This is great news when TB is still such a scourge in many parts of the world.